{
  "DOI": "10.1007/s10689-022-00294-0",
  "ISSN": [
    "1389-9600",
    "1573-7292"
  ],
  "URL": "http://dx.doi.org/10.1007/s10689-022-00294-0",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:p\u003eUniversal tumor DNA testing in epithelial ovarian cancer patients can function not only as an efficient prescreen for hereditary cancer testing, but may also guide treatment choices. This innovation, introduced as Tumor-First workflow, offers great opportunities, but ensuring optimal multidisciplinary collaboration is a challenge. We investigated factors that were relevant and important for large-scale implementation. In three multidisciplinary online focus groups, healthcare professionals (gynecologic oncologists, pathologists, clinical geneticists, and clinical laboratory specialists) were interviewed on factors critical for the implementation of the Tumor-First workflow. Recordings were transcribed for analysis in Atlas.ti according to the framework of Flottorp that categorizes seven implementation domains. Healthcare professionals from all disciplines endorse implementation of the Tumor-First workflow, but more detailed standardization and advice regarding the logistics of the workflow were needed. Healthcare professionals explored ways to stay informed about the different phases of the workflow and the results. They emphasized the importance of including all epithelial ovarian cancer patients in the workflow and monitoring this inclusion. Overall, healthcare professionals would appreciate supporting material for the implementation of the Tumor-First workflow in the daily work routine. Focus group discussions have revealed factors for developing a tailored implementation strategy for the Tumor-First workflow in order to optimize care for epithelial ovarian cancer patients. Future innovations affecting multidisciplinary oncology teams including clinical geneticists can benefit from the lessons learned.\u003c/jats:p\u003e",
  "alternative-id": [
    "294"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "1 November 2021"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 2,
      "value": "19 April 2022"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 3,
      "value": "16 May 2022"
    },
    {
      "group": {
        "label": "Declarations",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Conflict of interest",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "The authors have no conflicts of interest to declare that are relevant to the content of this article."
    },
    {
      "group": {
        "label": "Ethical approval",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 3,
      "value": "This study was assessed by the Medical Ethical Committee (CMO) of region Arnhem-Nijmegen who declared there was no need for ethical approval (Number 2021-7290)."
    },
    {
      "group": {
        "label": "Consent to participate",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 4,
      "value": "Verbal consent was asked for recording of the focus group discussions."
    },
    {
      "group": {
        "label": "Consent for publication",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 5,
      "value": "Participants were informed that anonymized data from focus group discussions could be used in scientific articles."
    }
  ],
  "author": [
    {
      "ORCID": "http://orcid.org/0000-0002-0684-3071",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Witjes",
      "given": "Vera M.",
      "sequence": "first"
    },
    {
      "ORCID": "http://orcid.org/0000-0003-0800-0630",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Braspenning",
      "given": "Jozé C. C.",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0003-2393-8141",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Hoogerbrugge",
      "given": "Nicoline",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Smolders",
      "given": "Yvonne H. C. M.",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0002-2521-4019",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Hermkens",
      "given": "Dorien M. A.",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0003-2385-2639",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Mourits",
      "given": "Marian J. E.",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0003-1290-1474",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Ligtenberg",
      "given": "Marjolijn J. L.",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0003-0305-3477",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Ausems",
      "given": "Margreet G. E. M.",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0001-5578-092X",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "de Hullu",
      "given": "Joanne A.",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Familial Cancer"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2022,
        5,
        16
      ]
    ],
    "date-time": "2022-05-16T02:06:01Z",
    "timestamp": 1652666761000
  },
  "deposited": {
    "date-parts": [
      [
        2023,
        1,
        13
      ]
    ],
    "date-time": "2023-01-13T15:46:25Z",
    "timestamp": 1673624785000
  },
  "funder": [
    {
      "DOI": "10.13039/501100004622",
      "award": [
        "KWF-KUN12732"
      ],
      "doi-asserted-by": "publisher",
      "name": "KWF Kankerbestrijding"
    }
  ],
  "indexed": {
    "date-parts": [
      [
        2024,
        2,
        5
      ]
    ],
    "date-time": "2024-02-05T11:11:42Z",
    "timestamp": 1707131502866
  },
  "is-referenced-by-count": 3,
  "issn-type": [
    {
      "type": "print",
      "value": "1389-9600"
    },
    {
      "type": "electronic",
      "value": "1573-7292"
    }
  ],
  "issue": "1",
  "issued": {
    "date-parts": [
      [
        2022,
        5,
        16
      ]
    ]
  },
  "journal-issue": {
    "issue": "1",
    "published-print": {
      "date-parts": [
        [
          2023,
          1
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2022,
            5,
            16
          ]
        ],
        "date-time": "2022-05-16T00:00:00Z",
        "timestamp": 1652659200000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2022,
            5,
            16
          ]
        ],
        "date-time": "2022-05-16T00:00:00Z",
        "timestamp": 1652659200000
      }
    }
  ],
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1007/s10689-022-00294-0.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1007/s10689-022-00294-0/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1007/s10689-022-00294-0.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "1-11",
  "prefix": "10.1007",
  "published": {
    "date-parts": [
      [
        2022,
        5,
        16
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2022,
        5,
        16
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2023,
        1
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.3389/fmolb.2018.00076",
      "author": "AP Sokolenko",
      "doi-asserted-by": "publisher",
      "first-page": "76",
      "journal-title": "Front Mol Biosci",
      "key": "294_CR1",
      "unstructured": "Sokolenko AP, Imyanitov EN (2018) Molecular diagnostics in clinical oncology. Front Mol Biosci 5:76. https://doi.org/10.3389/fmolb.2018.00076",
      "volume": "5",
      "year": "2018"
    },
    {
      "DOI": "10.3322/caac.21560",
      "author": "WS El-Deiry",
      "doi-asserted-by": "publisher",
      "first-page": "305",
      "issue": "4",
      "journal-title": "CA: Cancer J Clin",
      "key": "294_CR2",
      "unstructured": "El-Deiry WS, Goldberg RM, Lenz H-J et al (2019) The current state of molecular testing in the treatment of patients with solid tumors. CA: Cancer J Clin 69(4):305–343. https://doi.org/10.3322/caac.21560",
      "volume": "69",
      "year": "2019"
    },
    {
      "DOI": "10.1093/jnci/djz080",
      "author": "JR Vos",
      "doi-asserted-by": "publisher",
      "first-page": "161",
      "issue": "2",
      "journal-title": "J Natl Cancer Inst",
      "key": "294_CR3",
      "unstructured": "Vos JR, Fakkert IE, de Hullu JA et al (2020) Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition. J Natl Cancer Inst 112(2):161–169. https://doi.org/10.1093/jnci/djz080",
      "volume": "112",
      "year": "2020"
    },
    {
      "DOI": "10.1016/j.ejca.2016.03.009",
      "author": "M Arts-de Jong",
      "doi-asserted-by": "publisher",
      "first-page": "137",
      "journal-title": "Eur J Cancer",
      "key": "294_CR4",
      "unstructured": "Arts-de Jong M, de Bock GH, van Asperen CJ, Mourits MJ, de Hullu JA, Kets CM (2016) Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: a systematic review. Eur J Cancer 61:137–145. https://doi.org/10.1016/j.ejca.2016.03.009",
      "volume": "61",
      "year": "2016"
    },
    {
      "DOI": "10.1158/2159-8290.Cd-15-0714",
      "author": "PA Konstantinopoulos",
      "doi-asserted-by": "publisher",
      "first-page": "1137",
      "issue": "11",
      "journal-title": "Cancer Discov",
      "key": "294_CR5",
      "unstructured": "Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD (2015) Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov 5(11):1137–1154. https://doi.org/10.1158/2159-8290.Cd-15-0714",
      "volume": "5",
      "year": "2015"
    },
    {
      "key": "294_CR6",
      "unstructured": "National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 1.2022. Hereditary Cancer Testing Criteria. https://nccn.org. 24 Feb 2022"
    },
    {
      "DOI": "10.1200/jco.19.02960",
      "author": "PA Konstantinopoulos",
      "doi-asserted-by": "publisher",
      "first-page": "1222",
      "issue": "11",
      "journal-title": "J Clin Oncol",
      "key": "294_CR7",
      "unstructured": "Konstantinopoulos PA, Norquist B, Lacchetti C et al (2020) Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J Clin Oncol 38(11):1222–1245. https://doi.org/10.1200/jco.19.02960",
      "volume": "38",
      "year": "2020"
    },
    {
      "DOI": "10.1056/NEJMoa1810858",
      "author": "K Moore",
      "doi-asserted-by": "publisher",
      "first-page": "2495",
      "issue": "26",
      "journal-title": "N Engl J Med",
      "key": "294_CR8",
      "unstructured": "Moore K, Colombo N, Scambia G et al (2018) Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379(26):2495–2505. https://doi.org/10.1056/NEJMoa1810858",
      "volume": "379",
      "year": "2018"
    },
    {
      "DOI": "10.1016/j.ygyno.2021.05.011",
      "author": "J Lin",
      "doi-asserted-by": "publisher",
      "journal-title": "Gynecol Oncol",
      "key": "294_CR9",
      "unstructured": "Lin J, Sharaf RN, Saganty R et al (2021) Achieving universal genetic assessment for women with ovarian cancer: are we there yet? A systematic review and meta-analysis. Gynecol Oncol. https://doi.org/10.1016/j.ygyno.2021.05.011",
      "year": "2021"
    },
    {
      "DOI": "10.1186/s12913-017-2166-7",
      "author": "D Tremblay",
      "doi-asserted-by": "publisher",
      "first-page": "218",
      "issue": "1",
      "journal-title": "BMC Health Serv Res",
      "key": "294_CR10",
      "unstructured": "Tremblay D, Roberge D, Touati N, Maunsell E, Berbiche D (2017) Effects of interdisciplinary teamwork on patient-reported experience of cancer care. BMC Health Serv Res 17(1):218. https://doi.org/10.1186/s12913-017-2166-7",
      "volume": "17",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.ejca.2013.11.012",
      "author": "JM Borras",
      "doi-asserted-by": "publisher",
      "first-page": "475",
      "issue": "3",
      "journal-title": "Eur J Cancer",
      "key": "294_CR11",
      "unstructured": "Borras JM, Albreht T, Audisio R et al (2014) Policy statement on multidisciplinary cancer care. Eur J Cancer 50(3):475–480. https://doi.org/10.1016/j.ejca.2013.11.012",
      "volume": "50",
      "year": "2014"
    },
    {
      "DOI": "10.1093/annonc/mdx528",
      "author": "DL van der Velden",
      "doi-asserted-by": "publisher",
      "first-page": "3070",
      "issue": "12",
      "journal-title": "Ann Oncol",
      "key": "294_CR12",
      "unstructured": "van der Velden DL, van Herpen CML, van Laarhoven HWM et al (2017) Molecular tumor boards: current practice and future needs. Ann Oncol 28(12):3070–3075. https://doi.org/10.1093/annonc/mdx528",
      "volume": "28",
      "year": "2017"
    },
    {
      "DOI": "10.1093/jnci/djs502",
      "author": "NL Keating",
      "doi-asserted-by": "publisher",
      "first-page": "113",
      "issue": "2",
      "journal-title": "JNCI: J Natl Cancer Inst",
      "key": "294_CR13",
      "unstructured": "Keating NL, Landrum MB, Lamont EB, Bozeman SR, Shulman LN, McNeil BJ (2013) Tumor boards and the quality of cancer care. JNCI: J Natl Cancer Inst 105(2):113–121. https://doi.org/10.1093/jnci/djs502",
      "volume": "105",
      "year": "2013"
    },
    {
      "DOI": "10.1016/j.socscimed.2012.03.049",
      "author": "AE Powell",
      "doi-asserted-by": "publisher",
      "first-page": "807",
      "issue": "5",
      "journal-title": "Soc Sci Med",
      "key": "294_CR14",
      "unstructured": "Powell AE, Davies HT (2012) The struggle to improve patient care in the face of professional boundaries. Soc Sci Med 75(5):807–814. https://doi.org/10.1016/j.socscimed.2012.03.049",
      "volume": "75",
      "year": "2012"
    },
    {
      "DOI": "10.1016/j.socscimed.2015.12.002",
      "author": "EG Liberati",
      "doi-asserted-by": "publisher",
      "first-page": "31",
      "journal-title": "Soc Sci Med",
      "key": "294_CR15",
      "unstructured": "Liberati EG, Gorli M, Scaratti G (2016) Invisible walls within multidisciplinary teams: disciplinary boundaries and their effects on integrated care. Soc Sci Med 150:31–39. https://doi.org/10.1016/j.socscimed.2015.12.002",
      "volume": "150",
      "year": "2016"
    },
    {
      "DOI": "10.1186/1748-5908-8-35",
      "author": "SA Flottorp",
      "doi-asserted-by": "publisher",
      "first-page": "35",
      "issue": "1",
      "journal-title": "Implement Sci",
      "key": "294_CR16",
      "unstructured": "Flottorp SA, Oxman AD, Krause J et al (2013) A checklist for identifying determinants of practice: a systematic review and synthesis of frameworks and taxonomies of factors that prevent or enable improvements in healthcare professional practice. Implement Sci 8(1):35. https://doi.org/10.1186/1748-5908-8-35",
      "volume": "8",
      "year": "2013"
    },
    {
      "DOI": "10.1093/intqhc/mzm042",
      "author": "A Tong",
      "doi-asserted-by": "publisher",
      "first-page": "349",
      "issue": "6",
      "journal-title": "Int J Qual Health Care",
      "key": "294_CR17",
      "unstructured": "Tong A, Sainsbury P, Craig J (2007) Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 19(6):349–357. https://doi.org/10.1093/intqhc/mzm042",
      "volume": "19",
      "year": "2007"
    },
    {
      "key": "294_CR18",
      "unstructured": "Nederlandse Kankerregistratie (NKR), IKNL. https://iknl.nl/nkr-cijfers. 11 May 2021"
    },
    {
      "DOI": "10.1016/j.ygyno.2017.11.009",
      "author": "M Timmermans",
      "doi-asserted-by": "publisher",
      "first-page": "56",
      "issue": "1",
      "journal-title": "Gynecol Oncol",
      "key": "294_CR19",
      "unstructured": "Timmermans M, Schuurman MS, Ho VKY et al (2018) Centralization of ovarian cancer in the Netherlands: Hospital of diagnosis no longer determines patients’ probability of undergoing surgery. Gynecol Oncol 148(1):56–61. https://doi.org/10.1016/j.ygyno.2017.11.009",
      "volume": "148",
      "year": "2018"
    },
    {
      "DOI": "10.1186/1471-2288-13-117",
      "author": "NK Gale",
      "doi-asserted-by": "publisher",
      "first-page": "117",
      "issue": "1",
      "journal-title": "BMC Med Res Methodol",
      "key": "294_CR20",
      "unstructured": "Gale NK, Heath G, Cameron E, Rashid S, Redwood S (2013) Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol 13(1):117. https://doi.org/10.1186/1471-2288-13-117",
      "volume": "13",
      "year": "2013"
    },
    {
      "DOI": "10.1016/j.ygyno.2020.06.479",
      "author": "C Marchetti",
      "doi-asserted-by": "publisher",
      "first-page": "740",
      "issue": "3",
      "journal-title": "Gynecol Oncol",
      "key": "294_CR21",
      "unstructured": "Marchetti C, Minucci A, D’Indinosante M et al (2020) Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach. Gynecol Oncol 158(3):740–746. https://doi.org/10.1016/j.ygyno.2020.06.479",
      "volume": "158",
      "year": "2020"
    },
    {
      "DOI": "10.1053/j.seminoncol.2017.08.004",
      "author": "E Capoluongo",
      "doi-asserted-by": "publisher",
      "first-page": "187",
      "issue": "3",
      "journal-title": "Semin Oncol",
      "key": "294_CR22",
      "unstructured": "Capoluongo E, Ellison G, López-Guerrero JA et al (2017) Guidance statement on BRCA1/2 tumor testing in ovarian cancer patients. Semin Oncol 44(3):187–197. https://doi.org/10.1053/j.seminoncol.2017.08.004",
      "volume": "44",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.ygyno.2020.06.507",
      "author": "JM McCuaig",
      "doi-asserted-by": "publisher",
      "first-page": "747",
      "issue": "3",
      "journal-title": "Gynecol Oncol",
      "key": "294_CR23",
      "unstructured": "McCuaig JM, Care M, Ferguson SE, Kim RH, Stockley TL, Metcalfe KA (2020) Year 1: experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system. Gynecol Oncol 158(3):747–753. https://doi.org/10.1016/j.ygyno.2020.06.507",
      "volume": "158",
      "year": "2020"
    },
    {
      "DOI": "10.1136/ijgc-2020-002112",
      "author": "S Sundar",
      "doi-asserted-by": "publisher",
      "first-page": "272",
      "issue": "2",
      "journal-title": "Int J Gynecol Cancer",
      "key": "294_CR24",
      "unstructured": "Sundar S, Manchanda R, Gourley C et al (2021) British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA1/2 variants in ovarian cancer in the United Kingdom. Int J Gynecol Cancer 31(2):272–278. https://doi.org/10.1136/ijgc-2020-002112",
      "volume": "31",
      "year": "2021"
    },
    {
      "DOI": "10.1007/s10689-021-00277-7",
      "author": "K Bokkers",
      "doi-asserted-by": "publisher",
      "journal-title": "Fam Cancer",
      "key": "294_CR25",
      "unstructured": "Bokkers K, Zweemer RP, Koudijs MJ et al (2021) Positive experiences of healthcare professionals with a mainstreaming approach of germline genetic testing for women with ovarian cancer. Fam Cancer. https://doi.org/10.1007/s10689-021-00277-7",
      "year": "2021"
    },
    {
      "DOI": "10.1016/j.jmoldx.2018.05.005",
      "author": "MM de Jonge",
      "doi-asserted-by": "publisher",
      "first-page": "600",
      "issue": "5",
      "journal-title": "J Mol Diagn",
      "key": "294_CR26",
      "unstructured": "de Jonge MM, Ruano D, van Eijk R et al (2018) Validation and implementation of BRCA1/2 variant screening in ovarian tumor tissue. J Mol Diagn 20(5):600–611. https://doi.org/10.1016/j.jmoldx.2018.05.005",
      "volume": "20",
      "year": "2018"
    },
    {
      "DOI": "10.1002/humu.23137",
      "author": "RD Weren",
      "doi-asserted-by": "publisher",
      "first-page": "226",
      "issue": "2",
      "journal-title": "Hum Mutat",
      "key": "294_CR27",
      "unstructured": "Weren RD, Mensenkamp AR, Simons M et al (2017) Novel BRCA1 and BRCA2 tumor test as basis for treatment decisions and referral for genetic counselling of patients with ovarian carcinomas. Hum Mutat 38(2):226–235. https://doi.org/10.1002/humu.23137",
      "volume": "38",
      "year": "2017"
    },
    {
      "DOI": "10.1016/j.ejca.2021.02.029",
      "author": "EM Bunnik",
      "doi-asserted-by": "publisher",
      "first-page": "405",
      "journal-title": "Eur J Cancer",
      "key": "294_CR28",
      "unstructured": "Bunnik EM, Dondorp WJ, Bredenoord AL, de Wert G, Cornel MC (2021) Mainstreaming informed consent for genomic sequencing: a call for action. Eur J Cancer 148:405–410. https://doi.org/10.1016/j.ejca.2021.02.029",
      "volume": "148",
      "year": "2021"
    },
    {
      "DOI": "10.7861/clinmedicine.14-4-436",
      "author": "N Rahman",
      "doi-asserted-by": "publisher",
      "first-page": "436",
      "issue": "4",
      "journal-title": "Clin Med",
      "key": "294_CR29",
      "unstructured": "Rahman N (2014) Mainstreaming genetic testing of cancer predisposition genes. Clin Med 14(4):436–439. https://doi.org/10.7861/clinmedicine.14-4-436",
      "volume": "14",
      "year": "2014"
    },
    {
      "DOI": "10.1007/s10689-019-00122-y",
      "author": "N Hallowell",
      "doi-asserted-by": "publisher",
      "first-page": "293",
      "issue": "3",
      "journal-title": "Fam Cancer",
      "key": "294_CR30",
      "unstructured": "Hallowell N, Wright S, Stirling D, Gourley C, Young O, Porteous M (2019) Moving into the mainstream: healthcare professionals’ views of implementing treatment focussed genetic testing in breast cancer care. Fam Cancer 18(3):293–301. https://doi.org/10.1007/s10689-019-00122-y",
      "volume": "18",
      "year": "2019"
    },
    {
      "DOI": "10.1002/1878-0261.12817",
      "author": "M Care",
      "doi-asserted-by": "publisher",
      "first-page": "80",
      "issue": "1",
      "journal-title": "Mol Oncol",
      "key": "294_CR31",
      "unstructured": "Care M, McCuaig J, Clarke B et al (2021) Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population-based testing program. Mol Oncol 15(1):80–90. https://doi.org/10.1002/1878-0261.12817",
      "volume": "15",
      "year": "2021"
    },
    {
      "DOI": "10.1186/s13012-019-0937-8",
      "author": "WT Gude",
      "doi-asserted-by": "publisher",
      "first-page": "90",
      "issue": "1",
      "journal-title": "Implement Sci",
      "key": "294_CR32",
      "unstructured": "Gude WT, Roos-Blom M-J, van der Veer SN et al (2019) Facilitating action planning within audit and feedback interventions: a mixed-methods process evaluation of an action implementation toolbox in intensive care. Implement Sci 14(1):90. https://doi.org/10.1186/s13012-019-0937-8",
      "volume": "14",
      "year": "2019"
    },
    {
      "DOI": "10.1002/cam4.2182",
      "author": "E Dicks",
      "doi-asserted-by": "publisher",
      "first-page": "3614",
      "issue": "7",
      "journal-title": "Cancer Med",
      "key": "294_CR33",
      "unstructured": "Dicks E, Pullman D, Kao K et al (2019) Universal tumor screening for Lynch syndrome: perceptions of Canadian pathologists and genetic counselors of barriers and facilitators. Cancer Med 8(7):3614–3622. https://doi.org/10.1002/cam4.2182",
      "volume": "8",
      "year": "2019"
    },
    {
      "DOI": "10.1038/gim.2015.43",
      "author": "JL Schneider",
      "doi-asserted-by": "publisher",
      "first-page": "152",
      "issue": "2",
      "journal-title": "Genet Med",
      "key": "294_CR34",
      "unstructured": "Schneider JL, Davis J, Kauffman TL et al (2016) Stakeholder perspectives on implementing a universal Lynch syndrome screening program: a qualitative study of early barriers and facilitators. Genet Med 18(2):152–161. https://doi.org/10.1038/gim.2015.43",
      "volume": "18",
      "year": "2016"
    },
    {
      "DOI": "10.1038/s41585-019-0237-8",
      "author": "S-Y Ku",
      "doi-asserted-by": "publisher",
      "first-page": "645",
      "issue": "11",
      "journal-title": "Nat Rev Urol",
      "key": "294_CR35",
      "unstructured": "Ku S-Y, Gleave ME, Beltran H (2019) Towards precision oncology in advanced prostate cancer. Nat Rev Urol 16(11):645–654. https://doi.org/10.1038/s41585-019-0237-8",
      "volume": "16",
      "year": "2019"
    },
    {
      "DOI": "10.1200/op.20.00399",
      "author": "T Scheinberg",
      "doi-asserted-by": "publisher",
      "first-page": "e204",
      "issue": "2",
      "journal-title": "JCO Oncol Pract",
      "key": "294_CR36",
      "unstructured": "Scheinberg T, Goodwin A, Ip E et al (2021) Evaluation of a mainstream model of genetic testing for men with prostate cancer. JCO Oncol Pract 17(2):e204–e216. https://doi.org/10.1200/op.20.00399",
      "volume": "17",
      "year": "2021"
    },
    {
      "DOI": "10.1038/s41575-021-00463-z",
      "author": "A Hayashi",
      "doi-asserted-by": "publisher",
      "journal-title": "Nat Rev Gastroenterol Hepatol",
      "key": "294_CR37",
      "unstructured": "Hayashi A, Hong J, Iacobuzio-Donahue CA (2021) The pancreatic cancer genome revisited. Nat Rev Gastroenterol Hepatol. https://doi.org/10.1038/s41575-021-00463-z",
      "year": "2021"
    }
  ],
  "reference-count": 37,
  "references-count": 37,
  "resource": {
    "primary": {
      "URL": "https://link.springer.com/10.1007/s10689-022-00294-0"
    }
  },
  "score": 0,
  "short-container-title": [
    "Familial Cancer"
  ],
  "source": "Crossref",
  "title": [
    "Healthcare professionals’ perspectives on implementation of universal tumor DNA testing in ovarian cancer patients: multidisciplinary focus groups"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "22"
}